Prostaglandin D2 Modulation for Hair Loss and Prostate Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for androgenetic alopecia, acne, rosacea, prostate cancer, and benign prostatic hypertrophy are inadequate in addressing the underlying mechanisms involving prostaglandin D2 levels and activity, which contribute to these conditions.
Innovation Solution
Contacting a subject with a compound or composition that decreases prostaglandin D2 levels or activity, or targets downstream signaling pathways, or uses a protein product of specific target genes to inhibit or stimulate hair growth, treat these conditions, and evaluate therapeutic efficacy by measuring PGD2 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for androgenetic alopecia, acne, rosacea, prostate cancer, and BPH are used, then these conditions are addressed to some extent, but the underlying mechanisms involving prostaglandin D2 levels and activity are not effectively targeted
Solution Approach 1:
The patent extracts and isolates the specific mechanism involving prostaglandin D2 levels and activity from the complex pathological processes of multiple diseases. By identifying PGD2 as a common underlying factor in androgenetic alopecia, acne, rosacea, prostate cancer, and BPH, the invention enables targeted intervention at this specific molecular level, thereby improving treatment reliability while addressing the previously untargeted mechanism.
Solution Approach 2:
The patent applies a universal approach by developing treatments that target prostaglandin D2 pathways for multiple different diseases. The same therapeutic strategy of modulating PGD2 levels or activity can be applied across diverse conditions including hair loss, skin disorders, and prostate diseases, thereby enhancing adaptability and versatility of the treatment approach while maintaining reliable efficacy through mechanism-based therapy.
2Reliability
If prostaglandin D2 levels are decreased to treat multiple conditions, then treatment efficacy is improved, but the complexity of targeting downstream signaling pathways increases
Solution Approach 1:
The patent segments the complex downstream signaling pathways of prostaglandin D2 into distinct targetable components. By identifying specific receptors and signaling molecules in the PGD2 pathway, the invention breaks down the complex mechanism into manageable segments that can be targeted individually, thereby reducing the perceived complexity while maintaining effective treatment through multi-point intervention in the signaling cascade.
Solution Approach 2:
The patent introduces intermediary molecules and compounds that mediate between prostaglandin D2 and its downstream effects. These intermediary agents can modulate the signaling pathway at various points, providing a bridge that simplifies the interaction between PGD2 and its complex downstream targets, thereby improving treatment efficacy while managing the complexity of the signaling network through controlled intermediate steps.
Data Source
AI summary
This invention provides methods of treating androgenetic alopecia (AGA), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (BPH), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin D2 (PGD2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin D2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analogue or mimetic thereof; and methods of testing for AGA and evaluating therapeutic methods thereof, comprising measuring PGD2 levels.